Vestal Point Capital, LP Ascendis Pharma A/S Call Options Transaction History
Vestal Point Capital, LP
- $1.34 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ASND
# of Institutions
227Shares Held
56.7MCall Options Held
142KPut Options Held
259K-
Ra Capital Management, L.P. Boston, MA10.1MShares$1.27 Billion20.78% of portfolio
-
Westfield Capital Management CO LP Boston, MA4.96MShares$624 Million3.41% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.3MShares$540 Million0.93% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.2MShares$528 Million7.81% of portfolio
-
Janus Henderson Group PLC London, X03.92MShares$493 Million0.29% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $7.02B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...